DUBLIN, October 17, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Glaucoma Treatment Drugs Market Forecast to 2020 - New Product Launches Expected to Boost Market" report to their offering.
The "Global Glaucoma Treatment Drugs Market Forecast to 2020 - New Product Launches Expected to Boost Market" report provides a comprehensive analysis of the glaucoma treatment drugs market. The report includes the market share contributed by the sales of generic and patented drugs globally for treatment of glaucoma.
Further, the market in the study is differentiated by various parameters such as drug classes which include prostaglandin analogues, alpha agonist, beta blockers, carbonic Anhydrase inhibitors, cholinergic, and combined medications.
On the basis of formulation, glaucoma treatment drugs market is categorized into topical eye drops, semisolid dosage forms and pills. The market is also segmented by six geographical regions across the globe - North America, Europe, Asia Pacific, Middle East, Latin America, and Rest of the World.
Global Glaucoma Treatment Drugs Market:
Glaucoma being the second common cause of blindness globally has emerged as a worldwide problem. It was estimated that approximately - million people were affected with glaucoma worldwide in year 2013. The statistics clearly advocates the high demand for glaucoma treatment drugs across the globe. It has been estimated that glaucoma treatment drugs generated USD - million of revenue in 2010. However, the revenue declined at a high rate till 2013, owing to the expiry of major patented drugs including - and -. Although as a result of increasing prevalence of glaucoma, the market experienced steady growth afterwards and the market was valued at USD - million in 2015. Aging population and rising awareness in the emerging economies owing to the efforts of the government and NGOs were the major reasons which assisted the market in its growth during this period.
Glaucoma Treatment Drugs Market Segmentation:
On the basis of drug class, Prostaglandin analogues dominated the glaucoma treatment drugs market with revenue share of -% in 2015 owing to its efficacy to treat glaucoma and presence of two high revenue generating patented drugs including Travatan Z and Lumigan. Additionally, high sales of off-patent drug Xalatan also help the segment in generating high revenue. Beta blockers with revenue share of -% in 2015 followed prostaglandin analogues majorly due to high preference for these drugs in India and China.
High prevalence of glaucoma, high awareness among people and economic stability to undergo expensive treatment options are the major factors which have driven the glaucoma treatment drugs market in North America. Approximately - million people in the US were affected from glaucoma in 2015. Low cost of the drugs in Europe with strong reimbursement and high presence of patient pool in Asia Pacific regions helped these respective regions capture second and third position in the global glaucoma treatment drugs market. Europe captured -% share, by revenue followed by Asia Pacific with revenue share of -% in the global market in 2015.
Generic versus Branded Glaucoma Drugs:
Glaucoma being a highly prevalent disease demands for effective and affordable treatment options. Low cost of generic drugs is the major factor which has resulted in high adoption of generic drugs in the market. It has been observed that branded drugs cost approximately five times that of generic drugs. However, low efficacy of generic drugs restricts the ophthalmologists in prescribing generic drugs over patented drugs in economically stable countries. It has been noted that generic drugs show diverse bioequivalence with change in temperature. In addition to this bottle's material, shape, and size, delivery dose drop size, and different pH also impacts the efficacy of generic drug, resulting in more number of side effects and higher time frame treatment.
Wide distribution network in addition to patented product portfolio including Lumigan and Alphagen/Combigan assisted Allergan in gaining second position in the market. Pfizer Inc. and Akorn Inc. captured third and fourth position in the market respectively. High sales of off-patent drug Xalatan helped Pfizer in attaining respective position in the market.
Key Topics Covered:
1. Executive Summary
2. Research Methodology
4. Global Glaucoma Treatment Drugs Market Size, 2010 - 2015
5. Global Glaucoma Treatment Drugs Market Segmentation
6. Snapshot on North America Glaucoma Treatment Drugs Market
7. Snapshot on Europe Glaucoma Treatment Drugs Market
8. Snapshot on Asia Pacific Glaucoma Treatment Drugs Market
9. Global Glaucoma Treatment Drugs Market Competitive Landscape
10. Snapshot on Patented Glaucoma Treatment Drugs Market
11. Generic Versus Branded Glaucoma Drugs
12. Pipeline Analysis of Global Glaucoma Treatment Drugs Market
13. Trends and Developments in Global Glaucoma Treatment Drugs Market
14. Porter's Five Forces Analysis for Global Glaucoma Treatment Drugs Market
15. Future of Global Glaucoma Treatment Drugs Market
16. Analyst Recommendations
17. Macroeconomic Indicators
- Aerie Pharmaceuticals
- Akorn Inc.
- Allergan plc
- Bausch & Lomb Incorporated
- Inotek Pharmaceuticals
- Merck & Co. Inc
- Pfizer Inc
- Santen Pharmaceutical Co. Ltd
For more information about this report visit http://www.researchandmarkets.com/research/24sxbm/global_glaucoma
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets